Pulmocide Announces Successful Results from the OPERA-S Study: a Phase 2 Safety Study with Inhaled Opelconazole
April 15, 2024 08:00 ET
|
Pulmocide, Ltd.
Inhaled opelconazole observed to be generally well tolerated in this study as prophylaxis against pulmonary aspergillosis in lung transplant patients Discontinuations due to drug-related adverse...
Pulmocide Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 08:00 ET
|
Pulmocide, Ltd.
LONDON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing opelconazole for patients suffering from serious acute and chronic...
Pulmocide Announces New Clinical Data Confirming Low Potential for Drug-Drug Interactions with Inhaled Opelconazole
October 16, 2023 08:00 ET
|
Pulmocide, Ltd.
LONDON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and...
Pulmocide Announces Expansion of Management Team
June 08, 2023 07:00 ET
|
Pulmocide, Ltd.
LONDON, June 08, 2023 (GLOBE NEWSWIRE) -- Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and...
Pulmocide Raises $52 Million to Fund Additional Late-Stage Development of Opelconazole
December 06, 2022 07:00 ET
|
Pulmocide, Ltd.
LONDON, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and...
Pulmocide Receives Investment from the Cystic Fibrosis Foundation
December 06, 2021 08:00 ET
|
Pulmocide, Ltd.
The Cystic Fibrosis Foundation invested $3.5 million in Pulmocide as part of the CF Foundation’s Lung Transplant InitiativeFunding supports prophylaxis study in lung transplant patients LONDON,...